|
|
Blood, 15 April 2008, Vol. 111, No. 8, pp. 3968-3977.
Prepublished online as a Blood First Edition Paper on February 1, 2008; DOI 10.1182/blood-2007-10-117457.
Previous Article | Next Article 
Submitted October 17, 2007
Accepted December 18, 2007
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo*, Thierry Facon, Pieter Sonneveld, Joan Blade, Massimo Offidani, Francesca Gay, Philippe Moreau, Anders Waage, Andrew Spencer, Heinz Ludwig, Mario Boccadoro, and Jean-Luc Harousseau
Division of Hematology, University of Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
University of Lille, Lille, France
University Hospital, Erasmus Medical Center, Rotterdam, Netherlands
Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
Hematology Clinic, University of Ancona, Ancona, Italy
Hematology Department, University Hospital, Nantes, France
Department of Haematology, University Hospital Trondheim, Trondheim, Norway
Clinical Haematology and BMT, The Alfred Hospital, Melbourne, Australia
First Department of Medicine, Center for Oncology and Haematology, Wilhelminenspital, Vienna, Austria
Hospital Hotel-Dieu, Nantes Cedex, France
* Corresponding author; email: appalumbo{at}yahoo.com.
Thalidomide, bortezomib and lenalidomide have recently changed the treatment paradigm of myeloma. In young newly diagnosed patients, the combination of thalidomide and dexamethasone has been widely used as induction treatment before autologous transplant (ASCT). In two randomised studies, consolidation or maintenance with low-dose thalidomide has extended both progression-free and overall survival in patients who received ASCT at diagnosis. In elderly newly diagnosed patients, two independent randomised studies have reported that the oral combination of melphalan and prednisone plus thalidomide (MPT) is better than the standard melphalan and prednisone (MP). These studies have shown better progression-free survival, and two have shown improved overall survival for patients assigned to MPT. In refractory-relapsed disease, combinations including thalidomide with dexamethasone, melphalan, doxorubicin or cyclophosphamide have been extensively investigated. The risks of side-effects are greater when thalidomide is used in combination with other drugs. Thromboembolism and peripheral neuropathy are the major concern. The introduction of anticoagulant prophylaxis has reduced the rate of thromboembolism to less than 10%. Immediate thalidomide dose-reduction or discontinuation when paresthesia is complicated by pain or motor deficit has decreased the severity of neuropathy. Future studies will define the most effective or the best sequence of combinations which could improve life expectancy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Keller, G. Sollberger, and H.-D. Beer
Thalidomide Inhibits Activation of Caspase-1
J. Immunol.,
November 1, 2009;
183(9):
5593 - 5599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Sonneveld
Thalidomide/dexamethasone in myeloma: a double-edged sword
Blood,
April 9, 2009;
113(15):
3394 - 3394.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ludwig, R. Hajek, E. Tothova, J. Drach, Z. Adam, B. Labar, M. Egyed, I. Spicka, H. Gisslinger, R. Greil, et al.
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Blood,
April 9, 2009;
113(15):
3435 - 3442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Brenner, A. Gondos, and D. Pulte
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Haematologica,
February 1, 2009;
94(2):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Johnson, S. Corthals, C. Ramos, A. Hoering, K. Cocks, N. J. Dickens, J. Haessler, H. Goldschmidt, J. A. Child, S. E. Bell, et al.
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Blood,
December 15, 2008;
112(13):
4924 - 4934.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Palumbo, S. Bringhen, A. M. Liberati, T. Caravita, A. Falcone, V. Callea, M. Montanaro, R. Ria, A. Capaldi, R. Zambello, et al.
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Blood,
October 15, 2008;
112(8):
3107 - 3114.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Argyriou, G. Iconomou, and H. P. Kalofonos
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Blood,
September 1, 2008;
112(5):
1593 - 1599.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|